

The next meeting of the Haywards Heath research group will take place on Tuesday 14th January, 2020 from 7-9pm. The topic selected for the meeting is the use and safety of biologics in inflammatory disorders. The papers for discussion at the meeting are listed below:

Maxwell LJ, Zochling J, Boonen A, *et al.* TNF-alpha inhibitors for ankylosing spondylitis.

Cochrane Database Syst Rev. 2015 Apr 18;(4):CD005468.

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005468.pub2/pdf/CDSR/CD005468/CD005468_abstract.pdf (Summary) and full review

<https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005468.pub2/epdf/full>
(119 pages – please think of the trees and view electronic copy)

Health Talk Online – patients' experiences of biologics in the treatment of RA.

<http://www.healthtalk.org/peoples-experiences/bones-joints/rheumatoid-arthritis/biologic-treatments-rheumatoid-arthritis-anti-tnf-anti-il-6-anti-b-cell-and-anti-t-cell>

Udalova I, Monaco C, Nanchahal J, Feldmann M. Anti-TNF Therapy. *Microbiol Spectr.*

2016 4(4). <https://www.ncbi.nlm.nih.gov/pubmed/27726761>

Sieper J, Deodhar A, Marzo-Ortega H, *et al.* Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. *Ann Rheum Dis.* 2017;76(3):571-592.

<https://www.ncbi.nlm.nih.gov/pubmed/27582421>

Minozzi S, Bonovas S, Lytras T, *et al.* Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. *Expert Opin Drug Saf.* 2016;15(sup1):11-34.

<https://www.ncbi.nlm.nih.gov/pubmed/27924643>

(54 pages – please think of the trees and view electronic copy)

Goh L, Jewell T, Laversuch C, Samanta A. Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A

systematic review of the evidence. *Rheumatol Int.* 2012;32(1):5-13.

<https://www.ncbi.nlm.nih.gov/pubmed/21800113>

Lloyd S, Bujkiewicz S, Wailoo AJ, *et al.* The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. *Rheumatology (Oxford).* 2010;49(12):2313-21.

<https://www.ncbi.nlm.nih.gov/pubmed/20566736>

Aardoom MA, Veereman G, de Ridder L. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease. *Int J Mol Sci.* 2019;20(10). pii: E2529.

<https://www.ncbi.nlm.nih.gov/pubmed/31126015>

Shivaji UN, Sharratt CL, Thomas T, *et al.* Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. *Aliment Pharmacol Ther.* 2019;49(6):664-680. <https://www.ncbi.nlm.nih.gov/pubmed/30735257>

Melo FJ, Magina S. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review. *Int J Dermatol.* 2018;57(12):1521-1532. <https://www.ncbi.nlm.nih.gov/pubmed/30028008>

Shovman O, Tamar S, Amital H, *et al.* Diverse patterns of anti-TNF- α -induced lupus: case series and review of the literature. *Clin Rheumatol.* 2018;37(2):563-568. <https://www.ncbi.nlm.nih.gov/pubmed/29063464>

Atzeni F, Grillo E, Masala IF, *et al.* Do Anti-TNF Blockers Increase the Risk of Lung Involvement in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? A Systematic Review. *Isr Med Assoc J.* 2016;18(3-4):154-5. <https://www.ncbi.nlm.nih.gov/pubmed/27228632>

Wang F, Lin X, Zhao Q, Li J. Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel disease: systematic review and duration-response meta-analysis. *Eur J Clin Pharmacol.* 2015;71(8):911-9. <https://www.ncbi.nlm.nih.gov/pubmed/26022220>